(Q34253705)

31 July 2017

title

Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma (English)

1 reference

31 July 2017

0 references

C Verpelli

2

0 references

Dario Neri

object named as

D Neri

6

0 references

author name string

M Pedretti

1

1 reference

31 July 2017

J Mårlind

3

1 reference

31 July 2017

G Bertani

4

1 reference

31 July 2017

C Sala

5

1 reference

31 July 2017

L Bello

7

1 reference

31 July 2017

language of work or name

English

0 references

publication date

24 August 2010

1 reference

British Journal of Cancer

31 July 2017

published in

1 reference

31 July 2017

volume

103

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

827-836

1 reference

describes a project that uses

31 July 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC2966626/fullTextXML

inferred from PubMed Central ID database lookup

cites work

The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

An integrated genomic analysis of human glioblastoma multiforme

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Dose translation from animal to human studies revisited

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Antibody-based targeting of the tumor vasculature

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Radioimmunotherapy of brain tumor.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Potent antibody therapeutics by design

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Antibody targeted drugs as cancer therapeutics

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

ED-B fibronectin as a target for antibody-based cancer treatments

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Tumour vascular targeting

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Vascular targeting agents as cancer therapeutics

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Current and future developments in the use of temozolomide for the treatment of brain tumours

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Temozolomide and treatment of malignant glioma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Elucidation of the mechanism enabling tumor selective prodrug monotherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Activity of temozolomide in the treatment of central nervous system tumor xenografts

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

The hypoxic response of tumors is dependent on their microenvironment.

6 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Selective targeted delivery of TNFalpha to tumor blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: accelerated tumorigenesis in the central nervous system and complete rejection in the periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Genetic pathways to glioblastoma: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966626

Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment

28 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Selective Expansion and Partial Activation of Human NK Cells and NK Receptor-Positive T Cells by IL-2 and IL-15

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

The Antibody-Mediated Targeted Delivery of Interleukin-15 and GM-CSF to the Tumor Neovasculature Inhibits Tumor Growth and Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605832

Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20736949

12 December 2020

inferred from PubMed ID database lookup

The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20736949

12 December 2020

inferred from PubMed ID database lookup

Monoclonal antibody therapy of cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20736949

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/SJ.BJC.6605832

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference